







miR-7 AND miR-34a SEQUENCE CLONING AND EXPRESSION IN A1235 
GLIOBLASTOMA CELL LINE 
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Abstract: miRNAs are small non-coding RNAs which have an important role in signalling circuits regulating different 
cell processes. miR-7 and miR-34a are known as tumour suppressors, and both of them can interfere with cell 
proliferation, differentiation, apoptosis and migration. We constructed plasmids containing pri-miRNA sequences for 
these two miRNAs and introduced them into the A1235 glioblastoma cell line. Clones containing increased expression 
of processed miR-7 and miR-34a were obtained. The proliferation and sensitivity to alkylation agent of transfected cells 
were similar to those of control cells. Our results indicate that an increase in miR-7 and miR34 expression alone in A1235 
glioblastoma cells is not sufficient to change their proliferation or sensitivity to the influence of alkylating agents. 
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INTRODUCTION 
MicroRNA (miRNA) discovery revealed a completely 
new world of cellular control mechanisms involved in 
transcription and translation. These mechanisms have 
developed as far back as in unicellular organisms and 
have been found to have a role in multicellular organism 
differentiation and regulation in both plants and 
animals.1 
miRNAs belong to the non-coding RNAs (ncRNA) 
which are classified into two groups according to their 
length, those longer than 300 nucleotides (nt) and the 
second group, shorter than 300 nt. The small ncRNAs 
are further divided into small interfering RNAs 
(siRNAs), Piwi-interacting RNAs (piRNAs) and 
miRNAs. The microRNAs are short RNA sequences of 
21-22 nt which take part in RNA silencing by binding to 
target sequences in mRNAs, typically resulting in 
repressed gene or protein expression.2 DNA sequences 
coding for miRNA are dispersed across the genome. 
Most of the canonical miRNAs in the human genome are 
coded within introns but can also be present within 
coding sequences. The biogenesis of miRNAs is under 
tight temporal and spatial control, and the miRNA 
expression programme depends on the cell and tissue 
type.  They are regulated by their promoters, still not 
well-characterized, which are usually transcribed by 
RNA pol II. miRNA genes are transcribed into primary 
miRNA (pri-miRNA) transcripts about 1 kb pairs long, 
which are further processed by Drosha-containing 
complexes. The resulting hairpin precursor miRNAs 
(pre-miRNAs) are transported to the cytoplasm, where 
the Dicer complex removes the loop region from pre-
miRNAs, releasing a small double stranded RNA 
molecule. One strand of the duplex is bound by 
Argonaute to form a miRNA-induced silencing complex 
(miRISC), which targets mRNAs for regulation.3, 4 
Transcriptional regulation outcomes by miRNAs can be 
mRNA destabilization or degradation, translational 
repression and, in some cases, even activation of gene 
expression. It is supposed that miRNA sequences 
perfectly matching mRNA lead to target molecule 
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miRNAs are not perfectly complementary to the target 
mRNA, and they lead to the decrease in protein 
expression. Most of the miRNAs target 3'UTR mRNA, 
but they can also pair coding RNA sequences.3, 4  
It is supposed that human cells are able to express more 
than 2500 miRNAs. Although their role in the regulation 
of many genes and their involvement in signalling 
circuits regulating processes such as differentiation and 
carcinogenesis is known, the question of how, in 
general, they choose their target mRNAs still remains. 
Hypothetically, each mRNA has numerous potential 
miRNA binding sites, so each miRNA has many 
possible targets. Yet, their activity is often cell-type 
specific, and their targets should be proven 
experimentally.3 
In this article, we cloned a DNA sequence for miR-7 and 
miR-34a, under the CMV promoter, in order to express 
them in a glioblastoma cell line. Both of these miRNAs 
are known to act as tumour suppressors, influencing cell 
proliferation and apoptosis.5, 6, 7 miR-7 is one of the most 
investigated miRNAs, conserved from annelids to 
humans and found to have a role in nerve cell 
differentiation and tumorigenesis.7 miR-34a is 
ubiquitously expressed, but with the highest expression 
level in the brain. It is involved in the signalling circuits 
of p53 and epithelial-mesenchymal master transcription 
factors and thus in the regulation of cell cycle arrest, 
apoptosis, senescence and migration.6 Changes in miR 
expression can also influence the cell sensitivity on 
chemotherapeutics. Expression of miR-34a can be 
upregulated by p53, and A1235 cells have wild type 
p53.5, 8 miR-7 was found to influence the expression of 
poly(ADP ribose) polymerase and possibly interfere 
with alkylation damage repair.9, 10 Our results indicate 
that an increase in miR-7 and miR34 expression alone in 
A1235 glioblastoma cells is not sufficient to change 




MATERIAL AND METHODS 
Amplification of DNA sequences for miRNA and 
cloning into plasmids 
pri-miR DNA sequences were amplified from genomic 
DNA isolated from the glioblastoma cell line A1235. 
DNA was isolated using a standard procedure.11 
Sequences were amplified using specific primers and Q5 
High-Fidelity DNA Polymerase (New England Biolabs, 
USA) according to the manufacturer's protocol. Primers 
for pri-miR-7-2 were: F: 5'- 
GGAAGAGAGAAATGAGCCACTTGC-3' and R: 5'- 
GTATTCCTGCCACAGTGGGGGATG-3'.7 For 
sequence amplification, after denaturation on 98°C for 
30 s, a gradient PCR was employed for 38 cycles, raising 
the annealing temperature from 55 to 60°C. Primers for 
miR-34a were determined using NCBI databases 
(https://www.ncbi.nlm.nih.gov) and IDT tools for 
primer design (https://eu.idtdna.com/pages), and they 
were: F: 5'-CTCAAGTGATCCTCCTGTCTTG-3'  and 
R: 5'- GGACTCCACGTTCATCTCTAAG-3'. For miR-
34a, the conditions were: 98°C for 45 s, followed by 38 
cycles comprising 98°C for 15 s, 58°C for 30 s and 72°C 
for 1 min and finishing with elongation on 72°C for 2 
min. Amplified sequences were cut from the agarose gel 
and purified using Wizard SV Gel and PCR Clean-Up 
System (Promega, USA). A-overhangs were added to 
the sequence using Taq polymerase reaction,12 and the 
sequence was cloned into pGEM-T Easy vector 
(Promega, USA), according to the manufacturer's 
protocol. Plasmids were introduced into competent 
Escherichia coli XL10-Gold strain (Stratagene, USA) 
by chemical transformation, following the instructions 
from the manufacturer. White colonies grown on X-gal 
and IPTG agar plates were selected and analysed for the 
insertion. Plasmids containing the insertion were 
isolated using Wizard Plus SV Minipreps DNA 
Purification System (Promega), according to the 
protocol. 
DNA sequences cloned into pGEM vectors were cut out 
by EcoRI restriction endonuclease (New England 
Biolabs, USA) and cloned into pcDNA3 plasmid 
(Invitrogen, USA). pcDNA3 plasmid was first 
linearized by EcoRI and dephosphorylated on its 5' ends 
with calf intestinal alkaline phosphatase (CIAP, 
TaKaRa, Japan) and the insert was ligated in pcDNA3 
plasmid using T4 ligase (Promega). 
pcDNA3 plasmids with inserted sequences were 
introduced into E. coli by chemical transformation. 
Colonies positive for inserted sequences were detected 
by PCR reaction and the miR-34a and miR-7 DNA 
sequence orientation was determined by restriction 
digestion with PstI and XhoI, respectively, according to 
standard procedure (New England Biolabs). Chosen 
clones were sequenced (ABI Prism 310, Applied 
Biosystems). The control plasmid used was pcDNA3-
mRFP (pcDNA3-mRFP was a gift from Doug 




Cell culture, transfection and growth assessment 
Human glioblastoma cell line A1235 was grown in 
DMEM (Sigma-Aldrich, USA) with the addition of 10 
% foetal calf serum (Sigma-Aldrich), under the standard 
conditions.13 For transfection of control pcDNA-mRFP 
and cloned plasmids, Lipofectamine 3000 Reagent 
(Thermo Fisher Scientific, USA) was used according to 
the manufacturer's protocol. Cells were selected for two 
weeks in 400 µg/mL geneticin (Merck, Germany) to 
obtain stable colonies which were further isolated. The 
presence of the plasmid sequence in the cells was 
detected in the DNA isolated from the cells by PCR 
reaction using primers for CMV promoter (F: 5'-
CGTCAATGGGTGGAGTATTT-3' and R: 5'-
CGTGAGTCAAACCGCTATC-3'). The cell 
transfection with constructed plasmids was done several 
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tens of colonies) and single colonies (5-10 colonies for 
each transfection) were isolated. The analysis was done 
on pooled colonies.  
Cell microphotographs were taken by the inverted 
microscope Zeiss Axiovert 40 CFL. 
For growth curve, cells were seeded in a 48-well plate 
and every day one set of cells was counted on the 
haemocytometer grid under the light microscope 
(Axiovert 40 CFL, Zeiss). Trypan blue exclusion test 
was used for viable cell detection. For growth 
assessment in the presence of chemotherapeutics, cells 
were treated with 5 and 10 μM N-methyl-N'-nitro N-
nitrosoguanidine (MNNG) (a kind gift from dr. B. 





For miRNA detection in the cells, total RNA was 
isolated using TRI reagent (Sigma-Aldrich) according to 
the manufacturer's protocol. For miRNA detection, 
TaqMan Advanced miRNA Assays (Applied 
Biosystems, USA) were used with predesigned primers 
and probes (hsa-miR 34a-5p, Assay ID 47048, Assay 
A25576; hsa-miR-7-5p, Assay ID 478341, Assay 
A25576). As a control miR, hsa-miR-432-5p was used 
(Assay ID 478090). qRT-PCR was done on 7500 Fast 




Data were statistically analyzed using the software 
package Microsoft Office. The significance of 
independent   two-tailed   Student’s   t-test  was set   at 
p-value <0.05. 
RESULTS 
pcDNA3-miR-34a and pcDNA3-miR-7 plasmid 
construction 
To determine the effect of miR-34a and miR-7 on the 
A1235 glioblastoma cell line, we constructed two 
expression plasmids containing the sequences for each 
miRNA. DNA sequences coding for pri-miRNAs were 
cloned into the pcDNA3 plasmid to allow the cell 
machinery to do the pri-miRNA processing.4, 7 The pri-
miRNA sequences for miR-34a and miR-7-2 were 
cloned as DNA sequences of 1293 nt and 975 nt 
respectively, using specific primers and genomic DNA. 
Both sequences were first cloned by TA-cloning into 
pGEM plasmids and then recloned into pcDNA3. The 
sequences were checked by restriction analysis and 
sequencing (data not shown). Maps of cloned plasmids 
pcDNA3-miR-7 and pcDNA3-miR-34a are presented 
on Figure 1. 
 
 
miR expression in the glioblastoma cell line 
To see the effect of the plasmids pcDNA3-miR-7 and 
pcDNA3-miR-34a expression in the A1235 cells, 
plasmids were introduced into the cells by transfection, 
and stable clones were obtained after antibiotic 
selection. The morphology of the cells transfected by 
each of the plasmids was the same as the parental 
(Figure 2).  The presence of the transfected plasmids was 
checked on DNA isolated from the clones, by PCR 
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Figure 2. Microphotography of A1235 cells in cultures showing the morphology of parental A1235 cells and cells transfected with plasmids 
coding for red fluorescent protein RFP, miR-7 and miR-34a. RFP: A1235 cells transfected with plasmid coding for RFP; miR-7: cells transfected 
with plasmid coding for primiR-7; miR-34a: cells transfected with plasmid coding for primiR-34a. Pictures were taken at magnification of 100x, scale 
bar = 50 µm. 
 
 
To analyze the expression of the processed miRNA, 
TaqMan Advanced miRNA Assay was used. Total RNA 
was isolated from cells transfected with pcDNA3-miR-
7, pcDNA3-miR-34a and control cells transfected with 
pcDNA3-mRFP. Specific TaqMan assays were used for 
the detection of miR-7-5p and miR-34a. According to 
assay protocol, the expression was compared to miR-
423 chosen as miR with a stable level of expression. The 
assay protocol is based on the ligation of the specific 
linkers to miRNAs and amplification of the ligated 
sequences. In the second step, sequences are amplified 
with miRNA-specific primers. The results obtained by 
miRNA amplification in the transfected cells are 
presented on Figure 3. Expression of both miRNAs was 
significantly increased in the corresponding clones. 
A1235 cells transfected with pcDNA3-miR-7 had 
around 100 times higher expression of miR-7 in 
comparison with cells transfected with pcDNA3-RFP 
and pcDNA3-miR-34a. Cells transfected with pcDNA3-
miR-34a had around 8 times higher expression of miR-




Growth of cells with increased expression of miRs 
As miR-34a and miR-7 are known as tumor suppressors, 
we analyzed the growth of A1235 cells transfected with 
miR plasmids. Cell growth was assessed by cell 
counting under the microscope. Growth curves obtained 
are presented in Figure 4. A. There was no significant 
growth inhibition in comparison with nontransfected 
cell and in comparison to cells transfected with control 
plasmid.  
We also compared the growth of the transfected cells in 
the presence of alkylating agent MNNG, to see if 
transfected miRs influence the cell DNA damage 
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Figure 3. Expression of miR-7 and miR-34a in the A1235 cells. The cells were transfected with plasmids pcDNA3-RFP (1), pcDNA3-miR-7 (2), 
and pcDNA3-34a (3), and expression of miR-7 and mir-34a was detected using TaqMan Advanced miRNA Assay and qRT-PCR. The relative 
expression was determined by comparison to the expression of the miR-432. A: The relative expression presented as ΔCT values; B: The relative 
expression presented as a fold change in comparison with control samples, cells transfected with pcDNA3-RFP plasmid * P<0.05. 
 
 
suppressors and influence cell cycle arrest and 
apoptosis. Therefore, we treated the cells with low 
concentrations of MNNG (5 and 10 µM) which cause 
the growth arrest in A1235 cells. A1235 cells are 
considered sensitive to alkylation damage.14 Figures 4. 
B and C show that the alkylation caused growth arrest in 
all cell strains similarly, and there were no significant 
differences in growth inhibition between control RFP 





miRNAs take part in the complex signaling circuits and 
are involved in the processes of differentiation, 
migration, proliferation, as well as in carcinogenesis.15 
Many miRNAs act as tumor suppressors and oncogenes, 
and the same miRNA can even have both of these roles 
depending on the tumor type. The two miRNAs, miR-7 
and miR-34a, which we expressed in a glioblastoma cell 
line act as tumor suppressors and belong to the most 
investigated miRNAs.  
Between 700 and 1000 genes were found in different 
cell types to be miR- 34a targets.5, 6, 16, 17 Many of them 
are linked to cell proliferation and growth, as well as 
tumorigenesis. miR-34a was found to be a target of p53, 
and thus involved in the cell cycle arrest, apoptosis and 
senescence as responses to DNA damage.5, 18 Beside 
regulation by p53, miR-34a can also be regulated p53- 
independently.5 The main signaling pathways 
influenced are TGF-beta, Wnt, MAPK, Notch and Akt, 
as miR-34a directly targets some of their members, such 
as Notch-1, Notch-2, CDK6, c-Met and Rictor.19 Also, 
its proapoptotic activities are exerted through the 
regulation of Bcl2, BIRC3 and other genes.5 It was 
found that this miR can take part in cellular 
reprogramming and expression of proteins linked with 
stem cell features, such as CD44, Sox and Nanog, as 
well as in epithelial-mesenchymal transition, 
influencing signaling circuits of its master transcription 









Figure 4. Proliferation and growth inhibition curves of normal and transfected glioblastoma A1235 cells after treatment with N-methyl N'-
nitro-N'-nitroso guanidine (MNNG). A: untransfected  (A1235) or cells transfected with pcDNA3-mRFP (RFP), pcDNA3-miR-34a (miR-34a) and 
pcDNA3-miR-7 (miR-7) were grown for 5 days and their proliferation followed by cell counting and Trypan blue exclusion test. B and C: cell line  
growth was followed after treatment with 5 µM (B) or 10 µM (C) MNNG. 
 
 
decreased in glioblastomas and its expression is often 
compromised during neuroblastoma development.21, 22 
Also, transient expression of mir-34a was found to 
decrease glioblastoma and neuroblastoma cell line' 
proliferation.22, 23 Because of its wide area of activities 
involved in tumor suppression, there were even attempts 
to use miR as a therapy for some solid and hematologic 
tumors.6, 24 
In our experiments, A1235 glioblastoma cells were 
transfected with a plasmid coding DNA for the miR-34a 
sequence. Using qPCR, it was shown that cells express 
an 8-fold increase in the amount of mature miR-34a. 
However, the cells did not show any morphology 
changes nor significant changes in the growth rate in 
comparison with the control cells. The explanation for 
these results can be the fact that colonies with a higher 
proliferation rate were isolated and the possibility that 
only cells which in some way overcame the arrest during 
the selection process of stable transfectants survived. 
Also, it is possible that the glioblastoma cell line used 
harbor mutations in molecules involved in Akt 
signaling, leading to the constitutive activation of this 
pathway, and thus developed resistance to miR 
modulation. Constitutive activation of the Akt pathway 
is often present in glioblastomas.25  
Treatment with DNA damaging alkylation agent caused 
cell arrest in A1235 cells, similarly in wild type and cells 
with increased expression of miR-34a. It is supposed 
that miR-34a is a downstream effector of p53, but 
having wild type p53, it is possible that its activation was 
sufficient for the arrest. We did not observe additional 
cell apoptosis.  
Another miR expressed in a glioblastoma cell line was 
miR-7, also considered a tumor suppressor and involved 
in the cell growth regulation It was found to 
downregulate the cell proliferation influencing EGFR 
expression and downstream Akt kinase and MAPK 
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molecules.7, 26 It can also regulate the expression of 
Ack1 (associated cdc42 kinase 1) and Pak1 (p21-
activated kinase 1) and interfere with the cell growth and 
migration,    angiogenesis,   as  well  as   with   
apoptosis.9, 27, 28, 29 Although it was found that miR-7 can 
also act as oncomir and increase the cell proliferation in 
several types of carcinoma, its expression is linked to the 
process of differentiation and inhibition of the 
proliferation in glioblastoma and nerve cells.30, 31 Its 
expression is often decreased in glioblastoma and other 
types of brain tumors in comparison with normal 
tissue.7, 28 It is detected as one of the miRNAs forming 
"miR signature" in neural stem and neural cancer stem 
cell.32  
In our experiments, A1235 cells with high expression of 
mature miR-7 were obtained. The cells were transfected 
with a miR DNA sequence, and the miR processing was 
dependent on the cellular machinery. The protocol used 
supposed the detection of processed miRNAs. It is 
interesting that Kefas et al.7 found specific regulation of 
miR and inhibition of the production of mature 
molecules despite the high expression of pri-miRNA. It 
was found that specific molecules expressed in some cell 
types bind to the conserved terminal loop of pri-miR-7 
and inhibit processing.33 The expression of these 
inhibitors seems to be regulated during the process of 
neural cell differentiation, during which miR-7-1 
processing increases and expression of inhibitor proteins 
decreases. Yet, some experiments were done on a 
glioblastoma cell line constitutively expressing high 
levels of processed miR-7, obviously not causing 
growth arrest.33 Jia et al.10 showed that glioblastoma cell 
line resistant to alkylation agents had low expression of 
miR-7, and its overexpression sensitized the cells to 
chemotherapeutics and suppressed the stemness of the 
cells. This miR-7 activity was found to be mediated by 
YY1 downregulation. A1235 cells with increased 
expression of miR-7 seemed to be resistant to 
proliferation inhibition. The reasons could be the same 
as in the case of miR-34a cells: selection of cells 
resistant to inhibition, either by its parental signaling 
background or by changes obtained during stable clone 
establishment. Another explanation, although 
hypothetical, can be the expression of specific miR-7 
inhibitors, such as possibly circular ciRS-7 (or 
CDRIas).34 The cells showed similar features as parental 
cells: treatment with MNNG caused growth arrest but 
not a significant decrease in the cell viability.  
To conclude, we detected an increase in the expression 
of the processed miRNAs, miR-7 and miR-34a, in the 
glioblastoma cell line A1235 transfected with 
expression plasmids containing DNA sequences for pri-
miRNAs. Although acting as tumor suppressors, miR-7 
and miR-34a did not have a significant influence on the 
cell growth and response to the chemotherapeutics in 
these settings. Further investigation is needed to 
analyses the activities and targets of miR-7 and miR-34a 
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